Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Vilon

KE, L-Lys-L-Glu, lysylglutamic acid

Quick Stats
Studies 40
Trials 100
Recruiting NA INTERVENTIONAL NCT06474507

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The most common cause of death for Chinese patients is ischemic cerebrovascular diseases(ICVD), particularly cerebral infarction. It places a heavy burden on people, families, and society as a whole and poses considerable risks of death and disability. The disease known as CSVD has a subtle beginning, is difficult to identify, and is frequently detected only after it progresses to the point of vascular cognitive dysfunction. The primary ischemia necrosis of brain nerve cells and the activation of inflammatory cells are their pathologic processes. According to historical Chinese medical documents, bezoar possesses properties that can help prevent seizures, treat strokes, enhance cognitive function and mental well-being, and stimulate alertness. Calculus Bovis Sativus (CBS) is the most authentic formulation of bezoar ingredients compared to other bezoar products. It has received approval from the China Food and Drug Administration for the essential treatment of comatose patients. CBS consists of three primary constituents: bilirubin, bile acids, and taurine. Scientific evidence has demonstrated that all of these components possess anti-inflammatory, antioxidant, and neuroprotective properties. The investigators' objective is to carry out an investigator-initiated clinical study to assess the efficacy of orally administered CBS in treating ischemic cerebrovascular diseases in humans.

Interventions

Name: Calculus bovis sativus (CBS)
Type: DRUG
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.

Primary Outcomes

Measure: The Modified Rankin Scale (mRS)
TimeFrame: Up to 12 weeks after treatment initiation
Description: To assess mRS of subjects within 12 weeks after treatment initiation
Measure: The National Institutes of Health Stroke Scale, NIHSS
TimeFrame: Up to 12 weeks after treatment initiation
Description: To assess NIHSS of subjects within 12 weeks after treatment initiation
Measure: Incidence and Severity of AEs and SAEs
TimeFrame: Up to 14 weeks after treatment initiation
Description: To evaluate the incidence of AEs and SAEs occurred within 14 weeks after treatment initiation

Trial Information

NCT ID

NCT06474507

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Tongji Hospital

Last Updated

December 15, 2025